UK-based Futura Medical plc has struck a deal with Cooper Consumer Health for the launch of its topical, gel-based erectile dysfunction (ED) treatment MED3000 across Europe.
Through an exclusive licensing agreement, Futura has granted Cooper the rights to commercialize MED3000 – a Class II(b) medical device – throughout the European Economic Area (which includes all 27 European Union member states,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?